MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026

November 16, 2026

MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026

Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential

YAVNE, Israel, November 16, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m. Eastern Time.

The event will bring together leading wound care experts to discuss the evolving treatment landscape for chronic wounds, clinical evidence supporting EscharEx®, MediWound's investigational biologic for debridement and facilitation of wound closure, and the ongoing pivotal Phase III VALUE study in venous leg ulcers (VLUs). The program will also explore the potential commercial opportunity for EscharEx in the U.S. market.

The event will feature distinguished experts in wound care and clinical research:

- **Vickie R. Driver, DPM** – Founding Chair, Wound Care Collaborative Community; Professor, Washington State University Elson S. Floyd College of Medicine
- **John C. Lantis II, MD** – Director of Advanced Wound Care, Mount Sinai Health System; Professor of Surgery, Icahn School of Medicine at Mount Sinai; Editor-in-Chief, *WOUNDS*
- **Cyaandi Dove, DPM** – Director of the Diabetes Foot Program, Division of Endocrinology, Diabetes and Clinical Nutrition and the Harold Schnitzer Diabetes Health Center, Oregon Health & Science University
- **Gabriele Brambilla, MBA** – Chief Executive Officer, Alira Health

They will be joined by MediWound's management team, including Ofer Gonen, Chief Executive Officer, and Aya Ben-Yaakov, PhD, Vice President, Clinical and Regulatory Affairs.

Key discussion topics will include:

- **Unmet needs in chronic wound care:** limitations of current treatment approaches, the potential role of novel biologic debridement therapies, and the FDA's evolving stance.
- **Evolving standards of care:** U.S. KOL consensus recommendations regarding optimal debridement practices for chronic wounds.
- **EscharEx clinical evidence:** Findings from three Phase II studies evaluating debridement, granulation tissue formation, biofilm reduction, wound closure, and safety, including comparative data versus SANTYL®.
- **Phase III VALUE study:** Trial design, key endpoints, and the planned interim sample size reassessment in patients with VLUs.
- **U.S. market potential:** Physician adoption, reimbursement considerations, and the assumptions underlying the Alira Health-estimated $1.05 billion U.S. annual peak sales potential.
- **Future development opportunities:** Upcoming clinical milestones and planned expansion into diabetic foot ulcers (DFUs) and pressure ulcers (PUs).

A live question-and-answer session will follow the presentations, providing participants with an opportunity to engage directly with the speakers and MediWound's management team. A replay of the event will be available on the Investors section of MediWound's website following the event.

To register for the virtual event, please visit the event registration page.

About EscharEx®

EscharEx is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement and facilitation of wound closure in chronic and hard-to-heal wounds. Designed for topical, once-daily use, EscharEx has shown wound bed preparation and was generally well tolerated in multiple Phase II studies. It enables rapid removal of non-viable tissue while promoting granulation tissue formation and reducing bioburden and biofilm. The global Phase III VALUE trial in venous leg ulcers

(VLUs) is underway, with additional clinical studies planned in diabetic foot ulcers (DFUs) and pressure ulcers (PUs). In Phase II studies, EscharEx showed potential advantages over standard-of-care treatments, including the leading enzymatic debridement agent, and targets a substantial global market opportunity.

About MediWound Ltd.

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The Company's FDA-approved biologic, NexoBrid®, is indicated for eschar removal in patients with thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound's late-stage development candidate, EscharEx®, is an investigational therapy for the debridement and facilitation of wound closure in chronic wounds, with the potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "continues," "believes," "guidance," "outlook," "target," "future," "potential," "goals" and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions.
Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives, anticipated timelines, outcome of future periodic DSMB reviews, expectations and commercial potential of our products and product candidates, including EscharEx®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submissions by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our contracts with governmental agencies; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and product candidates; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; geopolitical risks, including armed conflict; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on March 5, 2026 and Reports on Form 6-K and other filings with the SEC from time to time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound does not undertake, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

MediWound Contacts:

Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com